Novel HIV vaccine phase 1 clinical trial testing produces promising results
A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
Red-colored H9-T cell that had been infected by numerous, spheroid-shaped, mustard-colored human immunodeficiency virus (HIV) particles
Image/NIAID
“This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well,” says William Schief, PhD, a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI’s Neutralizing Antibody Center, whose laboratory developed the vaccine. “With
This new approach is aimed at the immune system in the production of broadly neutralizing antibodies
This approach has opened opportunities for vaccine development against other viruses as well
After decades of searching for an HIV vaccine, a scientist has finally made a breakthrough with a new approach to developing a vaccine against the virus. The findings of the trial were presented at the International AIDS Society HIV Research for Prevention conference.
Promising results
The phase one clinical vaccine trial is an International AIDS Vaccine Initiative (IAVI) and Scripps Research project.
The vaccine candidate stimulated production of rare immune cells needed to start the process of generating broadly neutralising antibodies, and 97% of 48 participants who received the vaccine candidate showed the desired response.
Loading video.
VIDEO: A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of. view more
Credit: Scripps Research
NEW YORK and LA JOLLA, CA A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.